<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019642</url>
  </required_header>
  <id_info>
    <org_study_id>120-6371</org_study_id>
    <nct_id>NCT01019642</nct_id>
  </id_info>
  <brief_title>Vitamin D, C-reactive Protein and Insulin Resistance</brief_title>
  <official_title>Effect of Vitamin D Supplementation on C-reactive Protein and Insulin Resistance in Postmenopausal Women With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Salud Publica, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ellison Medical / International Nutrition Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Salud Publica, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo-controlled clinical trial of vitamin D supplementation
      (cholecalciferol, 4,000 IU/day for 6 months, in 104 postmenopausal women with type 2 diabetes
      mellitus.

      The objective was to evaluate the effect of vitamin D supplementation on C-reactive protein
      (CRP) and insulin resistance in women with type 2 diabetes mellitus (T2DM).

      The trial was conducted from March to October 2008 at the Hospital of the Mexican Social
      Security in Cuernavaca, Mexico.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods. Randomized, double blind, placebo-controlled clinical trial. We selected 104
      postmenopausal women, ages 45 to 65, with uncomplicated T2DM and BMI ≥25. Women with history
      of kidney or liver disease, BMI&gt;40, autoimmune disease or cancer were not included in the
      study.

      Participants were randomly assigned to receive either a capsule containing 4,000 IU of
      vitamin D3 (cholecalciferol, n=52) or placebo (n=52), once a day during 6 months.

      Outcome variables were serum CRP, measured with a high-sensitivity assay (nephelometry), and
      HOMA-IR. Serum vitamin D (25-OH-D) was measured by HPLC. Outcome variables were measured at
      baseline, and 3 and 6 months thereafter. All participants received diet and physical activity
      counseling, and visited the clinic for medical check-up once a month.

      Baseline Results. Mean age was 56.8 ± 5.1 y. Baseline BMI was 30.7 ± 3.9. Median CRP
      concentration was 5.0 mg/L (Interquartile range: 1.0, 8.5). HOMA index at baseline was 7.13 ±
      3.8. Serum 25-OH-D concentration at baseline was 54.5 ± 15.7 nmol/L (~22 ng/mL). Almost 94%
      of patients had baseline serum 25-OH-D levels &lt;80 nmol/L, and 25% were below 40 nmol/L. No
      one had levels &lt;20 nmol/L. There were no statistical differences on important variables by
      treatment group at the onset of study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum C-reactive protein concentrations, measured by a high-sensitivity assay -nephelometry-.</measure>
    <time_frame>3 and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin resistance, measured by HOMA-IR index</measure>
    <time_frame>3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum 25-OH-vitamin D3 levels</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Diabetes</condition>
  <condition>Low-intensity Chronic Inflammation</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol, 4,000 IU/d for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>4,000 IU per day during 6 months. Capsule form.</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>no active principles given.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus w/ &lt; 10 yrs of diagnosis

          -  Postmenopausal

          -  Overweight or obesity (BMI &gt;=25)

          -  Treated with metformin

        Exclusion Criteria:

          -  BMI &gt;=40

          -  Liver or kidney disease

          -  Other important chronic disease: i.e. cancer, autoimmune.

          -  Receiving insulin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario E Flores, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Salud Publica, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62450</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev. 2005 Dec;18(2):175-82. doi: 10.1079/NRR2005104.</citation>
    <PMID>19079903</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mario E. Flores</name_title>
    <organization>Instituto Nacional de Salud Publica</organization>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>diabetes</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

